Osteopore aims to introduce its bone healing technology to new markets, with China and US next on the list and TGA approval anticipated for Australia this year.
Bone healing biotech company Osteopore (ASX: OSX) has posted strong revenue growth since its ASX debut, eyeing China and the US as the next markets for its regenerative technology.
The Australian and Singapore-based business listed on the ASX last September after raising $5.25 million through its initial public offering and aims to become a world-leading producer of 3D-printed bioresorbable implants to assist with natural tissue regeneration.
Speaking with Small Caps, Osteopore executive director Geoff Pocock said the company’s technology has already been used in more than 30,000 surgeries across the globe, yet the potential to expand into different therapeutic areas and international markets is “massive”.
Osteopore is commercialising a range of unique, patented 3D-printed scaffolds designed to naturally dissolve over time, leaving only healthy bone tissue.
As Mr Pocock explains, bone “wants to regenerate” but if a piece of bone is removed, the remaining bone can’t heal across the void.
“The Osteopore scaffold provides that microstructure so the bone can grow through the scaffold and then, gradually, the scaffold dissolves and is naturally absorbed into the body,” he said.
Souce: Small Caps
Click here for the full article.